Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

(2012) Larry K Kvols et al.   ENDOCRINE-RELATED CANCER

Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology

(2012) Scott M. Knowles et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(2011) Dik J. Kwekkeboom et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

G protein-coupled receptors: novel targets for drug discovery in cancer

(2010) Rosamaria Lappano et al.   NATURE REVIEWS DRUG DISCOVERY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants

(2008) Mark Kidd et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY

Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas

(2008) Justyna Leja et al.   MODERN PATHOLOGY